Compared to Estimates, Avantor (AVTR) Q1 Earnings: A Look at Key Metrics

Core Insights - Avantor, Inc. reported $1.58 billion in revenue for Q1 2025, a year-over-year decline of 5.9$0.23, slightly up from $0.22 a year ago, with no EPS surprise against the consensus estimate [1] - The reported revenue was a surprise of -1.72$1.61 billion [1] Revenue Breakdown - Bioscience Production revenue was $516.40 million, below the four-analyst average estimate of$530.71 million [4] - Laboratory Solutions revenue reached $1.07 billion, slightly below the$1.09 billion average estimate [4] Operating Income Analysis - Adjusted Operating Income for Laboratory Solutions was $139 million, exceeding the average estimate of$128.24 million [4] - Adjusted Operating Income for Corporate was -$19.60 million, worse than the average estimate of -$14.91 million [4] - Adjusted Operating Income for Bioscience Production was $123.40 million, slightly above the average estimate of$121.23 million [4] Stock Performance - Avantor's shares returned -4.1% over the past month, compared to the Zacks S&P 500 composite's -4.8% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance in the near term [3]